GLP-1 Therapies Newsletter
Issue #35May 4, 20267 studies

Semaglutide linked to 2.5x higher risk of sudden vision loss

New research on GLP-1 drugs like semaglutide and tirzepatide reveals both promising benefits and unexpected risks across multiple health conditions.

🚨 Vision Loss Risk Emerges with Popular Weight Loss Drug

  • Meta-analysis of 1.6 million patients found semaglutide users had 2.52 times higher risk of nonarteritic anterior ischemic optic neuropathy (NAION) - sudden vision loss from blocked blood flow to the optic nerve

  • Risk was particularly high in diabetic patients (2.41x increased risk) with 118 cases per 100,000 semaglutide users annually

  • Five studies consistently showed this association, with 99.9% probability that the increased risk is real

Why it matters: NAION causes permanent vision loss and was previously considered rare, but this analysis suggests it may be an underrecognized side effect of the world's most popular weight loss medication.

🥉 Top 5% journal 🔗 Neurology Systematic Review 🗓️ Apr 30

Key Findings

🧠 Depression Motivation Gets Boost from Semaglutide

  • 72 people with major depression showed increased willingness to exert physical effort for rewards after 16 weeks of semaglutide treatment

  • The drug reduced "effort discounting" - making physical tasks feel less burdensome relative to potential rewards

  • Participants were more likely to choose difficult tasks when the expected payoff was higher

💡 May help explain why GLP-1 drugs could have broader mental health benefits beyond weight loss.
🥇 Top 1% journal 🔗 JAMA psychiatry Journal Article 🗓️ Apr 29

📊 Weight Loss Plateau Explained by Energy Math

  • Mathematical modeling showed semaglutide-induced weight loss peaks at 24% after 96 weeks, then plateaus for 78 weeks despite continued treatment

  • Energy intake initially dropped 32% in first 4 weeks but gradually rose to match energy expenditure by week 98

  • After stopping treatment, energy intake exceeded baseline levels, causing 5.3% weight regain

💡 Suggests combining GLP-1 drugs with behavioral therapy might be needed to sustain long-term weight loss.
Top 20% journal 🔗 Journal of the Academy of Nutrition and Dietetics Journal Article 🗓️ Apr 29

💊 Tirzepatide Shows Promise for Multiple Health Conditions

  • Meta-analysis of 25,847 patients found tirzepatide reduced heart failure events by 38% and resolved fatty liver disease in 62% of patients

  • Also linked to 21.9 fewer sleep apnea episodes per hour and 5.8 mmHg blood pressure reduction

  • Comprehensive analysis across 10 health domains showed benefits beyond diabetes and obesity

💡 Points to tirzepatide as a multi-organ protective therapy rather than just a diabetes or weight loss drug.
🔗 Endocr Pract Review 🗓️ Apr 30

🔬 Quintuple-Action Drug Outperforms Current Treatments

  • Scientists developed a single molecule combining GLP-1, GIP, and three PPAR receptor targets in mouse studies

  • This "quintuple agonist" reduced body weight and blood sugar more effectively than current GLP-1 drugs

  • Works by delivering anti-inflammatory effects directly to cells that express incretin receptors

💡 Could represent the next generation of obesity and diabetes treatments, though human trials are still needed.
🔗 Nature Journal Article 🗓️ Apr 29

🏥 Real-World Cancer Patient Protection Observed

  • GLP-1 drugs were linked to reduced heart damage in cancer patients receiving cardiotoxic treatments

  • Benefits were strongest in women, younger patients, and those with obesity or type 2 diabetes

  • Effects were particularly pronounced with anthracycline chemotherapy, a known heart-damaging treatment

💡 Suggests GLP-1 drugs might protect cancer patients' hearts during treatment, especially those with metabolic conditions.
🥉 Top 5% journal 🔗 Communications medicine Journal Article 🗓️ Apr 27

🧬 Genetics May Predict Drug Response and Side Effects

  • Two independent genetic variants near the GLP-1 receptor gene affect BMI through different pathways

  • One variant (rs12213929) influences diabetes risk independently of weight, while another (rs13216992) works primarily through body weight

  • People with 4 risk alleles had 0.47 kg/m² higher BMI than those with none

💡 Could help identify who will respond best to GLP-1 treatments and guide personalized dosing strategies.

Implications

While GLP-1 drugs continue showing benefits across multiple health conditions - from depression to cancer protection - the emerging vision loss risk highlights the need for careful monitoring. The combination of genetic insights and mathematical modeling suggests we're moving toward more personalized approaches to these powerful medications.

Studies in this issue

Primary sources used for this newsletter.

  1. Risk of Sudden Optic Nerve Damage Linked to Glucagon-like Peptide-1 Receptor Agonists
    main storyNeurology2026-04-30PMID 42060879
  2. Tirzepatide's potential health benefits beyond diabetes and obesity: A review and analysis
    key findingEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists2026-04-30PMID 42061648
  3. How diabetes drugs that target GLP-1 receptors may affect heart problems during cancer treatment
    key findingCommunications medicine2026-04-27PMID 42045526
  4. Understanding the Limits of Long-Term Treatment with GLP-1 Receptor Agonists Using Mathematical Modeling
    key findingJournal of the Academy of Nutrition and Dietetics2026-04-29PMID 42055215
  5. Combined activation of five hormone receptors improves obesity and diabetes in mice
    key findingNature2026-04-29PMID 42056522
  6. Separate Genetic Effects of the Glucagon-like Peptide-1 Receptor on Body Weight and Type 2 Diabetes
    key findingmedRxiv : the preprint server for health sciences2026-05-01PMID 42064929
  7. Semaglutide's impact on effort-related choices in major depression: A clinical trial
    key findingJAMA psychiatry2026-04-29PMID 42054055

Continue reading

All GLP-1 Therapies issues